Shingles Vaccine Market: Global Industry Analysis and Forecast 2029

Mayurikathade27 Mar, 2023Business

Shingles Vaccine Market was valued at USD 2.79 Billion in 2021, and it is expected to reach USD 6.02 Billion by 2029, exhibiting a CAGR of 10.1 % during the forecast period (2022-2029) Shingles is a painful rash that generally appears on one side of the body, most commonly the face or torso. Shingles vaccine is the only strategy to prevent shingles and postherpetic neuralgia (PHN), the most prevalent shingles consequence. Adults aged 50 and over receive two doses of the shingles vaccination Shingrix (recombinant zoster vaccine) to prevent shingles and its consequences. Adults 19 and older with compromised immune systems due to disease or therapy should additionally receive two doses of Shingrix since they are at a higher risk of developing shingles and accompanying problems.